Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
In a claimed world's first, Opyl is parterning with L39 Capital to launch a fund using robots to select stocks.